Kinase Inhibitor [EPC]

529988 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS NILOTINIB GEFITINIB SORAFENIB PALBOCICLIB AXITINIB LAROTRECTINIB LORLATINIB PAZOPANIB PRALSETINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 59449
1 FATIGUE 47546
2 DIARRHOEA 43735
3 OFF LABEL USE 36877
4 NAUSEA 30062
5 MALIGNANT NEOPLASM PROGRESSION 19698
6 ASTHENIA 18816
7 DECREASED APPETITE 17962
8 RASH 17627
9 VOMITING 16747
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 311 0.8544
1 ACQUIRED GENE MUTATION 673 0.5213
2 NEOPLASM PROGRESSION 16233 0.4732
3 TRYPTASE INCREASED 263 0.4015
4 CARBOHYDRATE ANTIGEN 15-3 INCREASED 252 0.3424
5 MYELOFIBROSIS 941 0.3272
6 METASTASES TO MENINGES 668 0.3160
7 HAEMATOCRIT ABNORMAL 366 0.3142
8 TUMOUR MARKER INCREASED 1346 0.2898
9 MANTLE CELL LYMPHOMA 411 0.2892
See all enriched reactions for Kinase Inhibitor [EPC]